Edition:
United Kingdom

Xenon Pharmaceuticals Inc (XENE.OQ)

XENE.OQ on NASDAQ Stock Exchange Global Market

3.60USD
16 Feb 2018
Change (% chg)

$-0.05 (-1.37%)
Prev Close
$3.65
Open
$3.65
Day's High
$3.65
Day's Low
$3.55
Volume
6,125
Avg. Vol
11,373
52-wk High
$9.90
52-wk Low
$2.15

Latest Key Developments (Source: Significant Developments)

Xenon Pharmaceuticals Expects To Have Ongoing XEN1101 Phase 1 Clinical Trial Completed By Mid-Year
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Xenon Pharmaceuticals Inc ::XENON PHARMACEUTICALS OUTLINES KEY MILESTONES FOR 2018.XENON PHARMACEUTICALS INC - EXPECT TO HAVE ONGOING XEN1101 PHASE 1 CLINICAL TRIAL COMPLETED BY MID-YEAR.XENON PHARMACEUTICALS INC - IN SECOND HALF OF THIS YEAR, ANTICIPATE HAVING COMPLETED XEN901 PHASE 1 CLINICAL TRIAL.XENON PHARMACEUTICALS INC - ANTICIPATE THAT BOTH XEN1101 AND XEN901 COULD BE IN PHASE 2 DEVELOPMENT BY END OF THIS YEAR.XENON PHARMACEUTICALS INC - AS OF DECEMBER 31, 2017, CASH AND CASH EQUIVALENTS AND MARKETABLE SECURITIES WERE $43.7 MILLION.XENON PHARMACEUTICALS INC - BASED ON CURRENT ASSUMPTIONS, XENON ANTICIPATES HAVING SUFFICIENT CASH TO FUND OPERATIONS INTO MID-2019.  Full Article

Xenon Pharma Says Entered Into Loan And Security Agreement With Silicon Valley Bank
Monday, 18 Dec 2017 

Dec 18 (Reuters) - Xenon Pharmaceuticals Inc ::XENON PHARMACEUTICALS- ON DEC 18, CO, UNIT ENTERED INTO LOAN AND SECURITY AGREEMENT WITH SILICON VALLEY BANK - SEC FILING.XENON PHARMACEUTICALS - PURSUANT TO AGREEMENT, BANK AGREED TO EXTEND TERM LOANS TO CO WITH AGGREGATE PRINCIPAL AMOUNT OF UP TO $15 MILLION.XENON PHARMACEUTICALS INC - BORROWINGS UNDER LOAN AGREEMENT WILL CONSIST OF UP TO THREE SEPARATE TRANCHES.  Full Article

Xenon Pharmaceuticals reports Q3 loss per share $0.43
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Xenon Pharmaceuticals Inc :Xenon Pharmaceuticals reports third quarter 2017 financial results and provides corporate update.Q3 revenue $300,000 versus $400,000.Xenon Pharmaceuticals Inc - qtrly loss per share $0.43.  Full Article

Xenon Pharma announces initiation of XEN1101 phase 1 clinical trial
Tuesday, 17 Oct 2017 

Oct 17 (Reuters) - Xenon Pharmaceuticals Inc :Xenon Pharmaceuticals announces initiation of XEN1101 phase 1 clinical trial.XEN1101 phase 2 proof-of-concept clinical trial anticipated to begin in Q3 2018​.Expect to file an IND equivalent application in Q4 of this year for XEN901​.  Full Article

Xenon Pharmaceuticals reports Q2 revenue $400,000 versus $4.0 million
Wednesday, 3 Aug 2016 

Xenon Pharmaceuticals Inc : Xenon pharmaceuticals reports second quarter 2016 financial results and provides corporate update .Q2 revenue $400,000 versus $4.0 million.  Full Article

Xenon Pharmaceuticals Q1 revenue $600,000 vs $4.0 mln
Tuesday, 10 May 2016 

Xenon Pharmaceuticals Inc : Xenon Pharmaceuticals Inc says net loss for quarter ended march 31, 2016 was $3.3 million, compared to net loss of $9.2 million for same period in 2015 . Xenon Pharmaceuticals reports first quarter 2016 financial results and provides corporate update .Q1 revenue $600,000 versus $4.0 million.  Full Article

Xenon Pharmaceuticals Inc says initiated phase 2 trial of XEN801 in moderate to severe acne
Tuesday, 8 Mar 2016 

Xenon Pharmaceuticals Inc:Reports 2015 financial results and provides corporate update.Says initiated phase 2 trial of xen801 in moderate to severe acne; results anticipated in fourth quarter of 2016.  Full Article

BRIEF-Xenon Pharmaceuticals Expects To Have Ongoing XEN1101 Phase 1 Clinical Trial Completed By Mid-Year

* XENON PHARMACEUTICALS INC - EXPECT TO HAVE ONGOING XEN1101 PHASE 1 CLINICAL TRIAL COMPLETED BY MID-YEAR